Vita Life Sciences Limited (VLS) AI Stock Analysis

• Market Cap: AU$133.33M
• Dividend Yield: 4.47%
• Average Volume (3M): 14.76K
• Price to Earnings (P/E): 14.7
• Beta (1Y): 0.12
• Revenue Growth: 8.46%
• EPS Growth: -1.95%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.09
• Shares Outstanding: 54,642,000
• 10 Day Avg. Volume: 12,408
• 30 Day Avg. Volume: 14,758
• PEG Ratio: -2.13
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 1.38
• P/FCF Ratio: 18.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: AU$2.50 ▲(1.63% Upside)

Vita Life Sciences demonstrates strong financial performance with robust revenue growth and profitability, contributing significantly to the overall score. The stock's technical indicators suggest a positive trend, though caution is advised due to potential overbought conditions. The valuation is reasonable, with a moderate P/E ratio and an attractive dividend yield.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a robust market position and successful product adoption, supporting long-term business expansion.

Low Debt Levels

Minimal leverage risk enhances financial stability and provides flexibility for future investments and growth opportunities.

Profitability

Strong profit margins reflect efficient operations and the ability to sustain profitability, contributing to long-term financial health.

Negative Factors

Cash Flow Management

Decreasing operating cash flow may pose challenges in managing liquidity and funding operations, impacting financial flexibility.

Earnings Growth

Negative EPS growth suggests potential issues in maintaining profitability, which could affect investor confidence and future earnings potential.

Operational Refinement

Inconsistent EBIT performance highlights the need for operational improvements to ensure stable earnings and efficiency.

Vita Life Sciences Limited Business Overview & Revenue Model

Company Description

Vita Life Sciences Limited (VLS) is an Australian-based health and wellness company specializing in the development, manufacturing, and marketing of dietary supplements and nutritional products. The company operates primarily in the health and wellness sector, focusing on providing innovative and high-quality products that cater to various consumer needs, including vitamins, minerals, and herbal supplements. VLS aims to enhance the quality of life for its customers through scientifically-backed formulations and a commitment to sustainability.

How the Company Makes Money

Vita Life Sciences Limited generates revenue through the sale of its health and wellness products, which are distributed through a variety of channels, including retail, e-commerce, and direct-to-consumer platforms. Key revenue streams include the sales of dietary supplements, vitamins, and herbal products, primarily targeting health-conscious consumers. The company also seeks to expand its market presence through strategic partnerships with retailers and distributors, as well as leveraging online sales platforms to reach a broader audience. Additionally, VLS invests in research and development to innovate and enhance its product offerings, which can lead to increased market share and customer loyalty, further contributing to its earnings.

Vita Life Sciences Limited Financial Statement Overview

Summary

Vita Life Sciences shows strong financial performance with impressive revenue growth and profitability. The company maintains a low debt-to-equity ratio and a high return on equity, indicating effective use of shareholder capital. However, there are challenges in managing cash flow fluctuations.

Income Statement

Vita Life Sciences has demonstrated strong revenue growth, increasing from $42.45 million in 2019 to $79.51 million in 2024, indicating a robust upward trajectory. Gross and net profit margins have consistently improved, with a gross profit margin of 59.4% and a net profit margin of 11.05% in 2024. The company maintains solid EBIT and EBITDA margins, reflecting efficient operations. However, slight fluctuations in EBIT indicate room for operational refinement.

Balance Sheet

The company's debt-to-equity ratio is impressively low, with a 0.01 ratio in 2024, indicating minimal leverage risk. With a return on equity of 16.78%, Vita Life Sciences effectively uses shareholder capital. The equity ratio of 72.85% demonstrates financial stability, though maintaining this balance while promoting growth remains essential.

Cash Flow

Operating cash flow to net income ratio is sound, supporting consistent free cash flow generation and covering capital expenditures comfortably. However, a reduction in operating cash flow from $12.98 million in 2023 to $6.16 million in 2024 suggests potential cash flow management challenges. Free cash flow to net income remains robust, contributing to financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	85.60M	79.50M	74.16M	66.89M	57.10M	46.48M
Gross Profit	51.65M	47.24M	42.60M	39.74M	34.81M	29.27M
EBITDA	12.83M	13.46M	13.10M	11.37M	11.71M	8.88M
Net Income	9.33M	8.78M	9.08M	7.08M	8.29M	6.09M
Balance Sheet
Total Assets	74.64M	71.89M	59.81M	51.80M	45.27M	39.10M
Cash, Cash Equivalents and Short-Term Investments	29.40M	28.60M	24.63M	15.69M	15.89M	14.48M
Total Debt	2.25M	517.00K	387.00K	601.00K	373.00K	2.07M
Total Liabilities	22.03M	19.61M	16.48M	15.30M	14.85M	14.66M
Stockholders Equity	52.71M	52.35M	43.40M	36.57M	30.75M	24.72M
Cash Flow
Free Cash Flow	9.17M	5.96M	12.32M	7.54M	5.73M	7.46M
Operating Cash Flow	10.09M	6.16M	12.98M	7.68M	5.89M	7.54M
Investing Cash Flow	-920.00K	-198.00K	-660.00K	-139.00K	-155.00K	-89.00K
Financing Cash Flow	-8.56M	-2.99M	-2.88M	-3.10M	-4.39M	-3.03M

Vita Life Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VLS, the sentiment is Positive. The current price of 2.46 is above the 20-day moving average (MA) of 2.42, above the 50-day MA of 2.42, and above the 200-day MA of 2.15, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.52 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VLS.

Vita Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VLS	75 Outperform	AU$133.33M	14.74	18.35%	4.47%	8.46%	-1.95%
VIT	59 Neutral	AU$41.09M	11.48	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	46 Neutral	AU$77.73M	690.00	0.19%	―	17.82%	―
AGH	41 Neutral	AU$19.03M	-1.28	―	―	-47.30%	82.53%
IDT	37 Underperform	AU$24.81M	-3.16	-35.58%	―	45.30%	-24.18%

Vita Life Sciences Limited Corporate Events

Vita Life Sciences Announces Cessation of Securities

Vita Life Sciences Limited announced the cessation of 104,392 ordinary fully paid securities as part of an on-market buy-back, effective November 24, 2025. This move is likely to impact the company’s capital structure and could influence its market positioning by potentially increasing shareholder value through a reduction in outstanding shares.

Vita Life Sciences Updates on Share Buy-Back Progress

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, reporting the purchase of 31,265 ordinary fully paid securities on the previous day, adding to a total of 507,413 securities bought back to date. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.

Vita Life Sciences Updates on Securities Buy-Back Program

Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 29,959 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 477,454 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Securities Buy-Back

Vita Life Sciences Limited has announced a daily update on their ongoing on-market buy-back of ordinary fully paid securities. As of November 6, 2025, the company has bought back a total of 434,286 securities, with an additional 4,954 securities purchased on the previous day. This buy-back strategy indicates the company’s efforts to optimize its capital structure and potentially enhance shareholder value.

Vita Life Sciences Announces Cessation of Securities via Buy-Back

Vita Life Sciences Limited announced the cessation of 226,873 of its ordinary fully paid securities due to an on-market buy-back, effective November 5, 2025. This move is part of the company’s capital management strategy, potentially impacting its market positioning by reducing the number of shares in circulation, which could influence shareholder value and market perception.

Vita Life Sciences Updates on Market Buy-Back Progress

Vita Life Sciences Limited has announced an update regarding their ongoing on-market buy-back of ordinary fully paid securities. As of October 31, 2025, the company has repurchased a total of 432,689 securities, with an additional 1,597 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Share Buy-Back Progress

Vita Life Sciences Limited has announced an update regarding its ongoing share buy-back program. As of October 30, 2025, the company has bought back a total of 416,311 securities, with an additional 16,378 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Buy-Back Program

Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, detailing the acquisition of 8,898 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 407,413. This buy-back initiative reflects the company’s strategic efforts to optimize its capital structure and potentially enhance shareholder value, signaling confidence in its financial health and future prospects.

Vita Life Sciences Updates on Market Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, reporting the acquisition of 20,418 ordinary fully paid securities on the previous day. This buy-back initiative, which began on May 22, 2025, is part of the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Share Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 372,413 securities bought back before the previous day and an additional 4,582 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially increase shareholder value.

Vita Life Sciences Continues Strategic Share Buy-Back

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program. The company reported the buy-back of 68,356 ordinary fully paid securities on the previous day, adding to a total of 289,032 securities bought back prior. This move is part of their strategy to manage capital efficiently, potentially improving shareholder value and market positioning.

Vita Life Sciences Updates on Share Buy-Back Progress

Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program. As of October 17, 2025, the company has repurchased a total of 287,413 ordinary fully paid shares, including 23,000 shares bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Share Buy-Back Progress

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 8,300 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 256,113 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure, potentially enhancing shareholder value and signaling confidence in its financial health.

Vita Life Sciences Updates on Market Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, with a total of 252,092 securities bought back prior to the previous day and an additional 4,021 securities acquired on the previous day. This buy-back initiative reflects the company’s strategy to enhance shareholder value and optimize its capital structure, potentially signaling confidence in its financial health and future performance.

Vita Life Sciences Updates on Share Buy-back Progress

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 12,824 ordinary fully paid securities bought back on the previous day. This move is part of a strategic effort to consolidate its share capital, potentially enhancing shareholder value and signaling confidence in the company’s financial health.

Vita Life Sciences Director Increases Shareholding

Vita Life Sciences Limited announced a change in the director’s interest, with Director Peter Osborne acquiring 2,000 ordinary shares through an on-market trade, increasing his total holdings to 43,184 shares. This transaction reflects the director’s confidence in the company’s future prospects and may positively influence stakeholder perceptions.

Vita Life Sciences Updates on Share Buy-Back Progress

Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program. As of September 19, 2025, the company has repurchased a total of 206,953 ordinary fully paid securities, with an additional 460 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program. As of September 18, 2025, the company has bought back a total of 202,701 ordinary fully paid securities, including 6,960 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Vita Life Sciences Updates on Securities Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, detailing the acquisition of 6,960 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 195,741. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, reflecting a commitment to financial health and market positioning.